(To see other currencies, click on price)
MORE ABOUT THIS BOOK
Main description:
The Symposium on New Drugs provides for an annual forum for academic investigators, research and development personnel from the pharmaceutical and related health care industries, and members of the Food and Drug Administration to discuss important clinical research issues. The Tenth Annual Symposium on New Drugs addressed the problem of whether it was still appropriate to approve antihypertensive agents soley on the endpoint of lowering cuff blood pressure. The initial discussions at this symposium related to the approaches and methods to studying antihypertensive agents. Dr. William Frishman provided a detailed list of the new approaches to the treatment of hypertension and pointed out the many new concepts that are currently active in the development of many new antihypertensive agents. Dr. William White detailed the growing importance of ambulatory blood pressure monitoring to define hypertension and to determine the change in blood pressure due to pharmacologically active agents. Dr. Jay Cohn pointed out the flaws in using cuff blood pressure and detailed the potential virtues of using vascular compliance to identify patients requiring treatment for hypertension. Dr. Thomas Pickering also discussed the potential value of evaluating changes in left ventricular hypertrophy a finding which identifies high risk patients who need to be included in clinical trials. Dr. Michael Weber detailed the issues and suggested refinements in the approaches to clinical trial designs for antihypertensive agents and Dr. Raymond Lipicky discussed the definition of dose-duration and the role of non-Mem and Peak/Through measurements in defining an antihypertensive drug effect.
Contents:
I. Approaches and Methods to Studying Antihypertensive Drugs.- 1. New concepts in antihypertensive drug therapy.- 2. Is ambulatory blood pressure monitoring required to define the hypertensive patient and to detect efficacy?.- 3. What vascular effects should be measured in antihypertensive drug research?.- 4. Is it necessary to demonstrate changes in left ventricular hypertrophy in the evaluation of antihypertensive drugs?.- 5. Clinical trials of antihypertensive agents.- 6. How does one define dose-duration of an antihypertensive drug? What is the role of non-Mem and the Peak/Through measurement.- Panel Discussion on Hypertension Methodology.- II. What Should be Required for FDA Approvability of a New Antihypertensive Drug?.- 7. What have we learned from prior clinical trials of antihypertensive drug therapy?.- 8. Are specific studies in elderly patients required for FDA approvability of a new antihypertensive drug?.- 9. Do we need any more antihypertensive drugs: The validity of a change in blood pressure as the only endpoint for approvability?.- 10. The cost and time to develop a new antihypertensive drug depending upon the endpoint.- Panel Discussion on Hypertensive Trial Design Issues.- III. Surrogate Endpoints to Define Risk VS. Benefits.- 11. What should be required for FDA approvability of a new antihypertensive drug? What is the FDA's viewpoint?.- 12. Are there valid surrogate endpoints for mortality that can be used to evaluate the effects of antiarrhythmic drug therapy?.- Panel Discussion on Surrogate Endpoints: Antiarrhythmic Agents.- 13. How to demonstrate the efficacy of a new drug for the treatment of chronic heart failure.- Panel Discussion on Surrogate Endpoints: Congestive Heart Failure Agents.- 14. Testing the relationship between cholesterol lowering and cardiovascular disease - past, present, and prospects.- Panel Discussion on Surrogate Endpoints: Hypolipidemic Agents.- Participant List.
PRODUCT DETAILS
Publisher: Springer (Springer-Verlag New York Inc.)
Publication date: October, 2011
Pages: 230
Weight: 379g
Availability: Available
Subcategories: Cardiovascular Medicine
From the same series
Jean-Claude Tardif
Xander H T Wehrens
Johan H. C. Reiber
Raimund Erbel
M.P. Sambhi
Pedro Brugada
W. Bleifeld
Naranjan S. Dhalla
Bohuslav Ostadal
Ralph Shabetai
Jason X.-J. Yuan
Hein J.J. Wellens
R. C. Becker
Franz H. Messerli
C.H. Peels
Stephen M. Factor
Hiroyuki Suga
Hugo Ector
Brian E. Jaski
Richard A. Walsh
Seymour Glagov
Michiel J. Janse
Lloyd W. Klein
Thomas H Marwick
Ernst E. van der Wall
P.J. Walter
Ernst E. van der Wall
Ernst E. van der Wall
A-M. Salmasi
Michel Emile Safar
A-M. Salmasi
Ernst E. van der Wall
Andrea Natale
Albert de Roos
C.A. Nienaber
Guillem Pons-Llado
Vinzenz Hombach
R. Vos
J. Candell-Riera
R.W. Stout
Peter Hanrath
Johan H. C. Reiber
P.A.F.M. Doevendans
Jack Rychik
P.A.F.M. Doevendans
P.E. Vardas
Makoto Nagano
George D. Dangas
Myrvin H. Ellestad
C.J. Preusse
Thomas H Marwick
Thomas H Marwick
Ernst E. van der Wall
G.T. Meester
A.G. Herman
J.C. Tardif
P.J. Walter
Johan H. C. Reiber
Ernst E. van der Wall
Lloyd W. Klein
Akira Matsumori
Robert L. Wilensky
Bernard Swynghedauw
Juan Carlos Kaski
Franz H. Messerli
John F. Keaney Jr.
Keith L. March
Naranjan S. Dhalla
Zainul Abedin
Juan Carlos Kaski
Eric J Topol
A.V. Bruschke
Richard C. Becker
J. Candell-Riera
Ghassan Bkaily
Lionel H. Opie
Bernard Swynghedauw
Geoffrey Burnstock
P. Cummins
Nicholas Sperelakis
Mina Rajskina
A.A. Knowlton
Johan H. C. Reiber
Irene D. Turpie
J. A. E. Spaan
Ernst E. van der Wall
Masatsugu Hori
Bing Liem Liong
R. Fagard
M. Iwase
R. Stroobandt
A.V. Bruschke
David M. Mirvis
Franz H. Messerli
G. Assmann
Melvin Scheinman
J. Morganroth
J.W. de Jong
M.B. Rosenbaum
C. Tissa Kappagoda
H.V. Villareal
J. Morganroth
Ernst E. van der Wall
Naranjan S. Dhalla
H. Mitchell Perry Jr.
M.P. Spencer
Henk Keurs
C.T. Lancée
J.R. Roelandt
G.S. Wagner
H. Kesteloot
A.C. Arntzenius
Johan H. C. Reiber
A. Maseri
Michel Emile Safar
M.P. Spencer
W. Bleifeld
Henk Keurs
Willem H. Birkenhager
Antonio Bayes de Luna
J.R. Roelandt
Naranjan S. Dhalla
H. Rijsterborgh
Marianne J. Legato
Naranjan S. Dhalla
S. Chien
Rafael Beyar
H.E. Van Dam
M.P. Spencer
J.R. Roelandt
Hilbert J.Th. Thalen
C. Marchesi
J.P.M Hamer
Rafael Beyar
L.N. Bouman
A. Alboni
Douglas P. Zipes
Nicholas Sperelakis
Borys Surawicz
Antonio Bayes de Luna
Johan H. C. Reiber
Hein J.J. Wellens
J.V. Chapman
E. Aliot
Vinzenz Hombach
Michael R. Rosen
William H. Gaasch
Pawan K. Singal
Robert Plonsey
H.L. Stone
J. Soler-Soler
Ernst E. van der Wall
Michel Emile Safar
J. Morganroth
Hein J.J. Wellens
J.R. Roelandt
Vinzenz Hombach
Richard S. Meltzer
Marvin A. Konstam
Naranjan S. Dhalla
Naranjan S. Dhalla
S.N. Willich
Johan H. C. Reiber
C.A. Nienaber
Ernst E. van der Wall
Robert J. Siegel
Markus Schwaiger
Andrew Wechsler
Elliot Rapaport
Naranjan S. Dhalla
John E. Tooke
Derek Yellon
Henk Keurs
Steve M. Teague
J.W. de Jong
Naranjan S. Dhalla
Nicholas Sperelakis
P.H. Heintzen
J. Morganroth
John B. Lombardini
Adam Schneeweiss
J.R. Roelandt
Naranjan S. Dhalla
Naranjan S. Dhalla
J.C. Chatham
Pim J. de Feyter
David W. Holt
Catherine A. Neill
J. Roelandt
A.P. Shepherd
Gastone Leonetti
Nico H.J. Pijls
K. Robinson
P.A.F.M. Doevendans
Douglas P. Zipes
Jose Marin-Garcia
Jonathan S. Steinberg
Francisco Villarreal
Dick Macdonald
Ragavendra R. Baliga
Dick Macdonald